Q1 Earnings Estimate for Lantheus Issued By Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz expects that the medical equipment provider will earn $1.32 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.57 EPS and FY2025 earnings at $5.77 EPS.

Several other analysts also recently weighed in on LNTH. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Down 2.4 %

Shares of LNTH stock opened at $81.39 on Thursday. Lantheus has a twelve month low of $56.06 and a twelve month high of $126.89. The company has a market cap of $5.66 billion, a P/E ratio of 13.54 and a beta of 0.44. The business has a fifty day simple moving average of $90.82 and a 200 day simple moving average of $97.32.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Moloney Securities Asset Management LLC acquired a new stake in shares of Lantheus in the third quarter valued at about $1,066,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the third quarter valued at about $25,955,000. Van ECK Associates Corp increased its stake in shares of Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after buying an additional 21,604 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after buying an additional 3,772 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.